Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi Biologics Acquires 90% Stake in CBC's Suzhou CDMO

publication date: Mar 18, 2021

Shanghai WuXi Biologics will acquire a 90% interest in CMAB Biopharma, a CDMO located in Suzhou. CMAB offers services that range from cell-line development, process development to clinical GMP manufacturing. It was backed by CBC Group and other investors including Ming Bioventures.  WuXi and CBC will collaborate to develop and manufacture biologic drugs for CBC portfolio companies. CBC was formerly known as C-Bridge Capital. Yesterday, WuXi Bio announced it would acquire Pfizer's biotech drug manufacturing facility in Hangzhou. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital